Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
F1000Prime Reports|November 7, 2014
Advances in treating acute myeloid leukemiaMargaret M Showel, Mark Levis
Case Reports in Oncology|April 8, 2015
Tyrosine kinase inhibitor induced isolated pericardial effusionVineet Agrawal, Eric S Christenson, Margaret M Showel
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 16, 2014
Isolated clonal cytogenetic abnormalities after high-dose therapyMargaret M Showel, Robert A Brodsky, Hua-Ling Tsai, et al.
Leukemia Research|January 21, 2014
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitroRobert L Dilley, Weijie Poh, Douglas E Gladstone, et al.
British Journal of Haematology|May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2017
Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant CyclophosphamideShannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2012
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemiasJudith E Karp, Brian M Thomas, Jacqueline M Greer, et al.
Pageof 2